Chène P - Search Results

1

The TEAD4-YAP/TAZ protein-protein interaction: expected similarities and unexpected differences.

Hau JC, Erdmann D, Mesrouze Y, Furet P, Fontana P, Zimmermann C, Schmelzle T, Hofmann F, Chène P. Hau JC, et al. Among authors: chene p. Chembiochem. 2013 Jul 8;14(10):1218-25. doi: 10.1002/cbic.201300163. Epub 2013 Jun 18. Chembiochem. 2013. PMID: 23780915

2

Dual specificity of Src homology 2 domains for phosphotyrosine peptide ligands.

Gay B, Furet P, García-Echeverría C, Rahuel J, Chène P, Fretz H, Schoepfer J, Caravatti G. Gay B, et al. Among authors: chene p. Biochemistry. 1997 May 13;36(19):5712-8. doi: 10.1021/bi962642y. Biochemistry. 1997. PMID: 9153411

3

A small synthetic peptide, which inhibits the p53-hdm2 interaction, stimulates the p53 pathway in tumour cell lines.

Chène P, Fuchs J, Bohn J, García-Echeverría C, Furet P, Fabbro D. Chène P, et al. J Mol Biol. 2000 May 26;299(1):245-53. doi: 10.1006/jmbi.2000.3738. J Mol Biol. 2000. PMID: 10860736

4

Discovery of potent antagonists of the interaction between human double minute 2 and tumor suppressor p53.

García-Echeverría C, Chène P, Blommers MJ, Furet P. García-Echeverría C, et al. Among authors: chene p. J Med Chem. 2000 Aug 24;43(17):3205-8. doi: 10.1021/jm990966p. J Med Chem. 2000. PMID: 10966738 No abstract available.

5

Coupling of the antennapedia third helix to a potent antagonist of the p53/hdm2 protein-protein interaction.

García-Echeverría C, Furet P, Chène P. García-Echeverría C, et al. Among authors: chene p. Bioorg Med Chem Lett. 2001 Aug 20;11(16):2161-4. doi: 10.1016/s0960-894x(01)00394-8. Bioorg Med Chem Lett. 2001. PMID: 11514160

6

Study of the cytotoxic effect of a peptidic inhibitor of the p53-hdm2 interaction in tumor cells.

Chène P, Fuchs J, Carena I, Furet P, García-Echeverría C. Chène P, et al. FEBS Lett. 2002 Oct 9;529(2-3):293-7. doi: 10.1016/s0014-5793(02)03362-8. FEBS Lett. 2002. PMID: 12372616 Free article.

7

Drugs targeting protein-protein interactions.

Chène P. Chène P. ChemMedChem. 2006 Apr;1(4):400-11. doi: 10.1002/cmdc.200600004. ChemMedChem. 2006. PMID: 16892375 Review.

8

Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity.

Maira SM, Stauffer F, Brueggen J, Furet P, Schnell C, Fritsch C, Brachmann S, Chène P, De Pover A, Schoemaker K, Fabbro D, Gabriel D, Simonen M, Murphy L, Finan P, Sellers W, García-Echeverría C. Maira SM, et al. Among authors: chene p. Mol Cancer Ther. 2008 Jul;7(7):1851-63. doi: 10.1158/1535-7163.MCT-08-0017. Epub 2008 Jul 7. Mol Cancer Ther. 2008. PMID: 18606717

9

Catalytic inhibition of topoisomerase II by a novel rationally designed ATP-competitive purine analogue.

Chène P, Rudloff J, Schoepfer J, Furet P, Meier P, Qian Z, Schlaeppi JM, Schmitz R, Radimerski T. Chène P, et al. BMC Chem Biol. 2009 Jan 7;9:1. doi: 10.1186/1472-6769-9-1. BMC Chem Biol. 2009. PMID: 19128485 Free PMC article.

10

Discovery of a new class of catalytic topoisomerase II inhibitors targeting the ATP-binding site by structure based design. Part I.

Furet P, Schoepfer J, Radimerski T, Chène P. Furet P, et al. Among authors: chene p. Bioorg Med Chem Lett. 2009 Aug 1;19(15):4014-7. doi: 10.1016/j.bmcl.2009.06.034. Epub 2009 Jun 13. Bioorg Med Chem Lett. 2009. PMID: 19560355

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

200 results

Search Page

Filters